XML 77 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition - Additional Information (Details)
$ in Millions
 1 Months Ended 12 Months Ended
Oct. 31, 2023
USD ($)
Aug. 31, 2022
USD ($)
Dec. 31, 2024
USD ($)
Obligation
Oct. 31, 2024
USD ($)
Aug. 31, 2023
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Reimbursement period of costs incurred for quarter ended     75 days    
GSK          
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Reimbursement period of costs incurred for quarter ended     75 days    
GSK Collaboration Agreement          
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Number of performance obligations | Obligation     6    
Pol Theta Program          
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Additional milestone payment potentially received clinical evaluation     $ 10.0    
Milestone payment received for achievement of earlier preclinical development milestone   $ 3.0      
Milestone payment received clinical evaluation         $ 7.0
Reimbursement period of costs incurred for quarter ended     90 days    
WRN Program          
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]          
Additional milestone payment potentially received clinical evaluation     $ 10.0    
Milestone payment received for achievement of earlier preclinical development milestone $ 3.0        
Milestone payment received clinical evaluation       $ 7.0  
Reimbursement period of costs incurred for quarter ended     75 days    
Determination period of costs incurred     75 days